Jonathan Riess, MD, on Zoldonrasib in Previously Treated Patients With KRAS G12D–Mutant NSCLC

April 20, 2026

Jonathan Riess, MD, of the University of California, Davis, describes preliminary data on the safety and clinical activity of zoldonrasib (also known as RMC-9805), an oral, RAS(ON) G12D–selective, tricomplex inhibitor, in previously treated patients with KRAS G12D–mutant non–small cell lung cancer (NSCLC) (Abstract CT021). 

Related Content